Spain – Highways consultancy services – Contrato de servicios de redacción del estudio informativo de la variante conjunta M-404 y M-311 en Belmonte de Tajo

Spain – Surveillance services – Servicio de seguridad y vigilancia, así como el mantenimiento de los sistemas de seguridad instalados en el campus de la Universidad Pablo de Olavide

Spain – Architectural, construction, engineering and inspection services – Asistencia Técnica para la maduración de la metodología y adaptación al plan BIM de la Autoridad Portuaria de Baleares

Spain – Repair and maintenance services of building installations – Servicio de mantenimiento de los edificios e instalaciones de la Sociedad de Promoción Económica de Gran Canaria

Spain – Civil engineering consultancy services – Prestación de los servicios de asistencia técnica necesarios para la redacción del proyecto de construcción y dirección facultativa de las obras (dirección de obras y coordinación de seguridad y salud, además de las asistencias técnicas complementarias necesarias) para la reurbanización integral y peatonalización de diversas calles del casco histórico de Arroyo de la Miel, Benalmádena

Spain – Miscellaneous engineering services – Prestación de un servicio de asistencia técnica al Consorcio de Residuos de la Región de Murcia (COREM) para la redacción del estudio de viabilidad económico-financiera, anteproyecto, preparación de pliegos y asistencia a la mesa de contratación para la posterior concesión de una planta de valorización energética de residuos municipales en la Región de Murcia.

Spain – Business development consultancy services – Servicios de diseño, coordinación y ejecución de un programa de mentoría y mejora competencial para mujeres de la IT Academy, orientado al empoderamiento y a la inserción laboral (Exp. 62-26).

The Genomics Research to Elucidate the Genetics of Rare Diseases:innovation (GREGoRi) initiative seeks to accelerate a paradigm shift in rare disease diagnosis by reimagining the tools, molecular technologies and analytical approaches used to identify the causal gene(s) and/or variant(s) underlying rare genetic disorders. This Notice of Funding Opportunity is intended to stimulate the development and testing of highly innovative experimental or computational approaches for rare disease diagnosis, that have the potential to make transformative improvements to the current state of the art.

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) along with other participating Institutes encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. Applicants are encouraged to leverage and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in cancer research.

The American Institute in Taiwan Public Diplomacy Section announces an open competition for one cooperative agreement to support the implementation of four Global Cooperation and Training Framework Classic workshops in Taiwan during calendar year 2027. The GCTF is a capacity building platform that brings together government officials, industry experts, academics, and civil society representatives to exchange practical experience and promote professional cooperation on emerging regional and global challenges. Workshop topics will be jointly identified by GCTF partners and may address resilience, emerging technologies, economic security, trusted supply chains, democratic governance, and other shared priorities. The selected recipient will serve as the implementation partner responsible for comprehensive operational and administrative support, including venue coordination, participant registration, international travel support, interpretation, audiovisual services, workshop materials, vendor coordination, site visits, monitoring and evaluation, and required grant reporting. Most workshops are expected to take place in Taipei, with one anticipated in southern Taiwan. AIT and GCTF partners will provide policy guidance, strategic direction, and substantive oversight. The project is intended to strengthen international cooperation, promote policy dialogue and capacity building, improve continuity across GCTF programming, and advance practical exchanges among government, industry, academia, and civil society.

This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, probiotics, and products marketed as dietary supplements), which have a strong scientific premise to justify further clinical testing. For this NOFO, natural products include promising nutritional regimens that standardize the amount of a specific naturally occurring nutritional compound (e.g., omega-3 fatty acids, anthocyanidins, or polyphenols) and have compelling preliminary evidence. Under this NOFO, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This NOFO will provide up to three years (R61 phase) of support for milestone-driven testing of pharmacokinetics, bioavailability, and assessment of the natural products effect (i.e., measure of mechanism of action) when used by humans on a specified target measure. If milestones in the R61 phase are achieved, up to 3 years of additional support (R33 phase) may be awarded to replicate the impact of the natural product on target engagement(s) when used by humans and assess whether there is an association between the degree of the impact on the target engagement and clinical outcomes in a participant population. Applications are encouraged to design R33 studies to determine how to optimize the impact of the natural product on the target engagement by optimizing the delivery of the natural product through examination of different doses or formulations. In addition, applications can be designed to combine the natural product with another treatment approach that is known to impact the same target engagement measure; or study the impact of the natural product in a population that is more responsive,